-
Product Insights
NewTesticular Cancer – Drugs In Development, 2024
Empower your strategies with our Testicular Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Testicular cancer stands out as a prevalent malignancy affecting men in the age group of 15 to 45 years. Its etiology is complex, involving a combination of genetic and environmental factors. Advancements in understanding the epidemiology, pathophysiology, and diagnostic approaches have paved the way for sophisticated management strategies. Notably, the prognosis for testicular cancer has significantly improved, boasting cure rates reaching up...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Salivary Gland Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Salivary Gland Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Nitrite in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sodium Nitrite in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sodium nitrite in Cystic Fibrosis Drug Details: Sodium nitrite (RESP301)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 3K3A-APC in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 3K3A-APC in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.3K3A-APC in Amyotrophic Lateral Sclerosis Drug Details:3K3A-APC is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-007 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-007 in Diffuse Large B-Cell Lymphoma Drug Details: TAK-007 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darinaparsin in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darinaparsin in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MPN-1 in Myeloproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MPN-1 in Myeloproliferative Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MPN-1 in Myeloproliferative Disorders Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GS-6779 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GS-6779 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GS-6779 in Hepatitis BDrug Details:GS-6779 is under development for the prevention of hepatitis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sovleplenib in Follicular Lymphoma Drug Details:Sovleplenib (HMPL-523) is under development for the treatment...
-
Thematic Analysis
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...